Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

SHE:300204 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	89.44	53.91	85.18	264.99	85.01	140.57
Short-Term Investments	-	-	-	-	-	120.73
Trading Asset Securities	-	-	-	-	381.46	461.24
Cash & Short-Term Investments	89.44	53.91	85.18	264.99	466.47	722.54
Cash Growth	42.00%	-36.71%	-67.86%	-43.19%	-35.44%	-8.52%
Accounts Receivable	45.97	39.07	61.22	188.18	157.9	128.22
Other Receivables	0.7	0.64	1.14	1.38	1.18	1.29
Receivables	46.67	39.72	62.35	189.56	159.07	129.51
Inventory	26.51	22.18	20.93	18.83	25.01	38.09
Prepaid Expenses	-	0.01	0.01	-	-	-
Other Current Assets	63.1	61.8	70.41	55.69	37.9	13.17
Total Current Assets	225.71	177.62	238.89	529.06	688.44	903.32
Property, Plant & Equipment	228.85	235	261.36	290.58	312.43	295.17
Long-Term Investments	481.19	514.07	549.54	522.25	545.43	444.03
Goodwill	19.75	19.75	19.75	19.75	22.17	22.17
Other Intangible Assets	34.48	34.67	35.13	80.48	82.22	82.97
Long-Term Deferred Tax Assets	50.08	50.08	164	198.13	155.84	79.87
Long-Term Deferred Charges	121.35	117.84	62.57	26.97	5.29	20.51
Other Long-Term Assets	0.84	0.58	0.98	2.09	15.15	8.17
Total Assets	1,162	1,150	1,332	1,669	1,827	1,856
Accounts Payable	36.12	33.49	72.91	35.87	31.71	19.63
Accrued Expenses	19.95	67.71	83.85	158.73	150.01	127.99
Short-Term Debt	20.01	42.42	40.95	23.09	-	48
Current Portion of Leases	0.06	0.06	-	2.69	2.25	-
Current Income Taxes Payable	2.18	-	-	0.02	-	-
Current Unearned Revenue	5.56	3.89	2.86	3.27	1.34	1.14
Other Current Liabilities	58.08	6.88	7.6	8.1	11.33	11.43
Total Current Liabilities	141.95	154.45	208.17	231.77	196.64	208.2
Long-Term Leases	-	0.06	-	3.18	5.37	-
Long-Term Unearned Revenue	29.18	29.91	29.24	33.47	21.32	23.35
Long-Term Deferred Tax Liabilities	48.43	48.43	74.14	47.03	52.91	33.83
Other Long-Term Liabilities	-	-	-	-	-	3.32
Total Liabilities	219.56	232.85	311.55	315.45	276.25	268.7
Common Stock	477.77	477.77	477.77	475.36	476.03	476.03
Additional Paid-In Capital	617.15	570.95	534.46	519.36	536.44	531.08
Retained Earnings	-241.71	-249.37	-83.63	314.62	510.98	648
Treasury Stock	-	-	-	-	-43.68	-82.72
Comprehensive Income & Other	100.22	129.88	92.06	44.53	70.97	15.11
Total Common Equity	953.43	929.23	1,021	1,354	1,551	1,588
Minority Interest	-10.73	-12.47	-	-	-	-
Shareholders' Equity	942.7	916.76	1,021	1,354	1,551	1,588
Total Liabilities & Equity	1,162	1,150	1,332	1,669	1,827	1,856
Total Debt	20.06	42.54	40.95	28.96	7.63	48
Net Cash (Debt)	69.37	11.37	44.23	236.03	458.84	674.54
Net Cash Growth	103.11%	-74.28%	-81.26%	-48.56%	-31.98%	-14.60%
Net Cash Per Share	0.15	0.02	0.09	0.49	0.97	1.42
Filing Date Shares Outstanding	477.77	477.77	477.77	475.36	472.66	469.65
Total Common Shares Outstanding	477.77	477.77	477.77	475.36	472.66	469.65
Working Capital	83.76	23.18	30.72	297.28	491.8	695.12
Book Value Per Share	2.00	1.94	2.14	2.85	3.28	3.38
Tangible Book Value	899.2	874.81	965.78	1,254	1,446	1,482
Tangible Book Value Per Share	1.88	1.83	2.02	2.64	3.06	3.16
Buildings	-	215.93	214.75	184.57	183.64	183.07
Machinery	-	317.62	318.38	254.98	246.28	237.66
Construction In Progress	-	-	-	87.82	85.48	52.92

Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.